No

Vaccine

The World Health Organization no longer recommends cholera vaccination for travel to or from cholera-endemic areas. Some countries may still require evidence of a complete primary series or a booster dose given within 6 months of arrival. Vaccination should not be considered as an alternative to continued careful selection of foods and water. Ideally, cholera and yellow fever vaccines should be administered at least 3 weeks apart.

C

Presence of any acute illness, history of severe systemic reaction, or allergic response following a prior dose of cholera vaccine

There is no data on the safety of cholera vaccination during pregnancy. Use in pregnancy should reflect actual increased risk. Persons who have had severe local or systemic reactions to a previous dose should not be revaccinated. Have epinephrine (1:1000) available for immediate use.

All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967.

Central nervous system: Malaise, fever, headache

Local: Pain, edema, tenderness, erythema, and induration at injection site

Decreased effect with yellow fever vaccine; data suggests that giving both vaccines within 3 weeks of each other may decrease the response to both

Refrigerate, avoid freezing

Inactivated vaccine producing active immunization

Children:

6 months to 4 years: Two 0.2 mL doses I.M./S.C. 1 week to 1 month apart; booster doses (0.2 mL I.M./S.C.) every 6 months

5-10 years: Two 0.3 mL doses I.M./S.C. or two 0.2 mL intradermal doses 1 week to 1 month apart; booster doses (0.3 mL I.M./S.C. or 0.2 mL I.D.) every 6 months

Children greater than or equal to 10 years and Adults: Two 0.5 mL doses given I.M./S.C. or two 0.2 mL doses I.D. 1 week to 1 month apart; booster doses (0.5 mL I.M. or S.C. or 0.2 mL I.D.) every 6 months

Do not give I.V.

No information available to require special precautions

No effects or complications reported

Local reactions can occur up to 7 days after injection

Defer immunization in individuals with moderate or severe febrile illness

Injection: Suspension of killed Vibrio cholerae (Inaba and Ogawa types) 8 units of each serotype per mL (1.5 mL, 20 mL)